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The coronavirus disease 2019 (COVID-19) pandemic, caused 
by severe acute coronavirus type 2 (SARS-CoV-2), has sig-
nificantly affected the lives of many people across North 
Carolina and the United States. Similar to the rest of the 
country, the epidemiology of SARS-CoV-2 in the state indi-
cates health disparities among Black and Hispanic/Latino 
individuals, the presence of hotspots, or counties with high 
numbers of infected persons, and clusters of transmission 
among congregate living facilities. There have been many 
advances in diagnostic methods for SARS-CoV-2 and thera-
pies for hospitalized patients nationwide. Public health strat-
egies have included widespread testing for SARS-CoV-2, 
optimal management of cases, contact tracing efforts, and 
a phased reopening of sectors/activities in North Carolina 
with masks and physical distancing to minimize spread of 
the virus. In this issue, several authors, researchers, and 
public health leaders discuss the challenges that North 
Carolinians have experienced with respect to COVID-19 
and several factors that are likely contributing to the health 
disparities among racial/ethnic minorities who have had 
the highest number of cases and deaths from SARS-CoV-2. 
Additional strategies also reported in this issue include the 
use of strike teams and mobile units to reach populations at 
high risk for infection and severe illness. Promoting individ-
ual and population-level strategies for minimizing transmis-
sion of SARS-CoV-2, especially among the most vulnerable, 
and consistent public health messaging based on science 
are critical as we face the new year and continued uncertain-
ties around the COVID-19 pandemic. 
Introduction
The pandemic caused by severe acute coronavirus type 2 (SARS-CoV-2) has been the most significant pandemic 
since the 1918 “Spanish Influenza” pandemic. Coronavirus 
disease 2019 (COVID-19), the illness caused by SARS-
CoV-2, has challenged all of us, from the ability of our sci-
entific and medical community to develop and implement 
widescale diagnostic, therapeutic, and preventive strategies 
to our public health infrastructure’s efforts to mitigate the 
impact locally and nationally. The first laboratory-confirmed 
case was reported in the United States on January 22, 2020. 
Only nine months later, as of October 21, the country had 
over 8 million reported cases of SARS-CoV-2 infection and 
over 200,000 deaths [1]. At that time, North Carolina had 
over 250,000 reported cases and over 4,000 deaths from 
COVID-19 [2]. 
Epidemiology and Health Disparities
Early data from the Centers for Disease Control and 
Prevention (CDC) identified the most vulnerable groups for 
COVID-19 as persons with underlying medical conditions 
(i.e., cardiovascular disease, diabetes, chronic lung disease), 
and older adults, with a startling death rate of 902/100,000 
among persons aged ≥ 80 years [3]. In comparison, the 
overall US death rate from SARS-CoV-2 infection was 
64/100,000 as of October 10, 2020 [1]. The reported death 
rate in North Carolina was lower than the national rate at 
35/100,000; however, 81% of deaths have been among 
people aged ≥ 65 [2]. Nationwide, persons aged 20–29 
years accounted for > 20% of all SARS-CoV-2 infections 
during June–August 2020 [4]. In North Carolina, persons 
aged 18-24 represent 16% of all cases, with individuals aged 
25-49 representing 40% of cases and 4% of deaths [2].
National surveillance data revealed the health dispari-
ties in COVID-19 associated with race/ethnicity of persons 
affected and area of residence. Compared to non-Hispanic 
whites, non-Hispanic Blacks had 2.6 times the risk for SARS-
CoV-2 infection and 4.7 times the risk of being hospitalized 
[5]; Hispanic/Latino persons had 2.8 times higher risk for 
infection and 4.6 times higher risk for hospitalization from 
COVID-19 [5]. Using cumulative county-level data collected 
during February–June 2020, the CDC identified US coun-
ties that were “hotspots,” based on algorithmic thresholds 
related to the number of new cases and the changes in inci-
dence [6]. Among all 18 hotspot counties identified in North 
Carolina, health disparities in COVID-19-associated mortal-
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ity were notable among Hispanics in each area [6]. 
The impact of health disparities on COVID-19 incidence 
is summarized by Dr. Corbie-Smith and colleagues in this 
issue [7]. They note that Black and Latino individuals are 
overrepresented in COVID-19 deaths in North Carolina, and 
that this is likely a result of inequities in housing, transporta-
tion, food access, and educational opportunity. Importantly, 
the authors provide several opportunities for reducing these 
disparities. In this issue, George Hendrix further discusses 
the impact of COVID-19 on the Hispanic and Latino com-
munity in the state, and notes that their barriers to health 
care include language and the fact that some are migrant 
workers [8]. He notes that a grassroots approach is critical 
to addressing health disparities in these groups. 
During a six-week period from June to mid-July 2020, the 
North Carolina Department of Health and Human Services 
(NCDHHS) reported a 183% increase in the incidence of 
COVID-19, from 7 to 19 per 100,000 persons per day [9]. 
However, differences between counties throughout the state 
are evident based on the COVID-19 Pandemic Vulnerability 
Index (PVI), which is calculated from key indicators including 
infection rates, baseline population concentration, current 
interventions, and health and environmental vulnerabilities 
(e.g., age distribution, health disparities, and hospital beds) 
[10 {preprint}]. Several North Carolina counties are in the 
top 100 counties with the highest PVI scores nationwide. 
One rural county located in Eastern North Carolina had a 
reported death rate of nearly 140/100,000 [11]. 
In a commentary that appears in this issue, Dr. Pettigrew 
identifies potential contributors to the vulnerability of some 
of our counties facing COVID-19 challenges, including rac-
ism, lack of universal health care access and workers’ pro-
tections, and defunded public health infrastructure [12]. 
Dr. Gerald also notes the specific impact of this pandemic 
on rural communities and provides recommendations for 
reducing health disparities [13].
Viral Transmission 
North Carolina has some of the top scientists in the world 
conducting research on SARS-CoV-2. The virus has ribo-
nucleic acid (RNA) as its genetic material, and is covered 
by a large number of “spike” (S) proteins on its surface that 
bind to specific receptors (angiotensin-converting enzyme 
2 receptors), allowing the virus to enter cells in the lungs 
and other organs; these S proteins serve as targets for some 
diagnostic assays and future vaccines [14]. The virus is zoo-
notic, probably originating from bats with spread to humans, 
although the range of other mammals that can become 
infected remains unknown. SARS-CoV-2 has been demon-
strated to spread from humans to other animals. NCDHHS 
reported the first dog in the state with laboratory-confirmed 
SARS-CoV-2 infection in August, but transmission from pets 
or livestock to humans appears rare [15]. 
SARS-CoV-2 is primarily transmitted through droplet 
transmission between persons within a short range (e.g., less 
than six feet), similar to other respiratory viruses (Table 1). 
The period of infectivity among most otherwise healthy 
people without immunosuppression is up to 10 days [16]; 
among immunocompromised or hospitalized patients, the 
period of infectivity may be up to 20 days. In addition, an 
infected person may be infectious starting from 48 hours (or 
two days) before symptoms or testing positive for COVID-19 
[16]. Furthermore, a significant proportion of persons with 
COVID-19 (estimated 40%-45%) may have subclinical or 
no symptoms and still transmit the virus [17]. 
The CDC has acknowledged the potential for airborne 
transmission of SARS-CoV-2, based on a few well-docu-
mented examples that occurred under special circumstances 
[18]. These circumstances involved enclosed spaces, pro-
longed exposure to respiratory particles that were generated 
with expiratory exertion (e.g., shouting, singing, exercising), 
and inadequate ventilation or air handling. The virus has 
been shown to remain viable in closed conditions for up to 
three hours and on certain surfaces for up to 72 hours [19] 
(Table 1), underscoring the need for frequent disinfection of 
potentially contaminated surfaces or shared objects with an 
EPA-approved disinfectant. Like similar enveloped viruses, 
SARS-CoV-2 is inactivated by 60%-90% alcohol-containing 
hand antiseptics within 15 seconds [20]. 
Transmission of SARS-CoV-2 infections is highest among 
close contacts (defined as individuals who have been within 
six feet of an infected person for a cumulative total of 15 
minutes or more over a 24-hour period) [16]. Among house-
holds with a laboratory-confirmed COVID-19 case, the over-
all secondary attack rate (defined as the probability that an 
infected individual will transmit the disease to uninfected 
persons) is estimated to be 18.8% [21 {preprint}], empha-
sizing the importance of education about home isolation 
for persons with mild SARS-CoV-2 infections. Persons with 
COVID-19 can generally discontinue isolation 10 days after 
symptom onset and after 24 hours with no fever, without the 
use of fever-reducing medications, and with improvement of 
other symptoms [22].
Testing and Surveillance
Over 3 million tests for SARS-CoV-2 have been con-
ducted in North Carolina to date, based on patient-level and 
aggregate data submitted electronically through the NC 
COVID-19 Surveillance System (NC COVID) and COVID-19 
Aggregate Test Reporting (eCATR) [2]. The overall positiv-
ity rate was 6.3% as of October 15, 2020 [2]. 
Local health departments have conducted most of the 
case investigations in the state after notification of cases in 
the North Carolina Electronic Disease Surveillance System 
(NC EDSS), which involves collection of information includ-
ing symptom onset, source of illness, activities during the 
case’s infectious period, and list of potentially exposed con-
tacts. Surveillance data are updated weekly on the COVID-19 
Dashboard [2], which also houses data regarding number of 
hospitalizations and cases diagnosed at North Carolina hos-
pitals. In this issue, Dr. Sickbert-Bennett and Lauren DiBiase 
describe in detail all the sources of COVID-19 surveillance in 
North Carolina and provide recommendations for improve-
ments to our current surveillance system [23].
Under the national declaration of a public health emer-
gency due to COVID-19, the United States Food and Drug 
Administration (FDA) has approved more than 200 diag-
nostic and antibody tests for SARS-CoV-2 detection under 
an Emergency Use Authorization (EUA) [24]. Several 
tests using polymerase chain reaction (PCR) assays that 
can detect the virus’s genetic material from respiratory 
specimens collected by either health care professionals 
or through self-collection in clinics or at home have been 
authorized for diagnosis of SARS-CoV-2; newer PCR-based 
tests using saliva as a specimen have also been authorized 
[24]. Furthermore, SARS-CoV-2 rapid antigen tests that 
have received EUAs can quickly detect fragments of proteins 
found on or within the virus by testing swabs collected from 
the nasal cavity, although antigen tests have substantially 
lower sensitivity.  
Diagnostic testing for SARS-CoV-2 is recommended for 
persons with symptoms of COVID-19 and for close contacts 
irrespective of symptoms. Some experts recommend that 
close contacts wait at least 5 days after last known exposure 
before testing; however, it is important to note that a nega-
tive test following an exposure to a person with COVID-19 
does not exclude infection if the contact is still within the 
14-day incubation period. Testing is also recommended for
individuals with higher risk of exposure or a higher risk of
severe disease if they become infected, regardless of symp-
toms (e.g., health care personnel, first responders, and
people in long-term care facilities, homeless shelters, and
correctional facilities) [25].
Other tests using blood samples have received EUAs 
for the qualitative detection of antibodies to SARS-CoV-2. 
Antibodies are generally detectable 1-3 weeks after symp-
tom onset, indicating the development of an adaptive 
immune response [26]. It is still unknown whether and to 
what degree an antibody response indicates immunity to 
future infection, and reinfection with SARS-CoV-2 has been 
reported in a small number of persons [27]. A study con-
ducted in North Carolina that enrolled outpatients and inpa-
tients across a health system representing 267 different zip 
codes identified a low prevalence of 0.8% for SARS-CoV-2 
based on antibody testing during late April through June 
[28]. A nationwide study reported that fewer than 10% of 
the adult population developed antibodies against SARS-
CoV-2 during the first wave of the pandemic [29]. 
table 1.
Characteristics of SARS-CoV-2, Therapeutic Options, and Infection Prevention 
Pathogen Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
Characteristicsa
Incubation period 2-14 days (median 4-5 days) 
Period of infectivity  2 days before symptom onset (or testing positive) to day 10 (immunocompetent); Up to 20 days  
(hospitalized and/or immunocompromised)
Transmission Respiratory droplets; direct contact and fomite; possibly airborne in special circumstances;b rare  
vertical transmissionc 
Duration in environment Up to 3 hours from aerosols; up to 72 hours on various surfacesd
Reproductive number (R0)e ~2-3 secondary cases (1.66 among high-density counties)f




Treatment for hospitalized patientsh Remdesivir, dexamethasone, prone ventilation
Infection preventiona
Preventive measures  Masks, physical distancing, hand-washing or alcohol-based hand sanitizers, disinfection of potentially  
contaminated surfaces and shared objects outside the home
Isolation period (ambulatory persons) 10 days from symptom onset and resolution of fever for at least 24 hours, without the use of fever- 
  reducing medications, and with improvement of other symptoms
Quarantine period  14 days since last exposure
Disinfection List N products approved by the EPA;i bleach solution containing 5.25%–8.25% sodium hypochlorite
EPA= Environmental Protection Agency 
aInformation from the Centers for Disease Control and Prevention for COVID-19, unless otherwise noted. 
bReference 18; 
cMeyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Ann Intern Med. 2020; M20-
5008. doi: 10.7326/M20-5008; 
dReference 19; 
eThe reproductive number means the average number of infected contacts per infected individual. 
fSy KTL, White LF, Nichols B. Population density and basic reproductive number of COVID-19 across United States counties. medRxiv. 2020. doi: 
10.1101/2020.06.12.20130021 (pre-print); 




The National Institutes of Health (NIH) created clinical 
criteria for defining the severity of illness from COVID-19, 
which have been useful in identifying appropriate therapies 
for individual patients (Table 2) [30]. Mild to moderate pul-
monary disease occurs in the majority (81%) of persons 
with symptomatic COVID-19. However, persons with severe 
to critical illness from SARS-CoV-2 can develop cardiac, 
hepatic, renal, hematological, neurological, and other com-
plications (e.g., thromboembolic events). In North Carolina, 
an estimated 51.1% of adults are at higher risk for severe 
COVID-19 illness based on age ≥ 65 years, having at least 
one underlying health condition, or both [2]. Multisystem 
inflammatory syndrome in children (MIS-C) and adults 
(MIS-A) can also result in multiorgan involvement [31]; as 
of October 10, 2020, there have been 43 cases of MIS-C 
reported in North Carolina [2]. In this issue, Dr. Rolfe and 
coauthors describe the frequency and numerous long-term 
sequalae of SARS-COV-2 infection observed among patients 
[32]. Importantly, persistent symptoms are common and 
may occur even among symptomatic patients who were 
never hospitalized.
The NIH has also issued COVID-19 treatment guidelines 
for patients depending on the severity of illness, based on 
scientific data and review from an expert panel that includes 
members from North Carolina academic institutions [28]. 
For mild to moderate illness from COVID-19, there are no 
specific therapies for persons managed at home that have 
been formally recommended at this time. For hospitalized 
patients, the FDA recently approved remdesivir, an intrave-
nous antiviral agent with activity against SARS-CoV-2, for 
use in adult and pediatric patients aged 12 and older and 
weighing at least 40 kilograms (about 88 pounds); younger 
children may be provided remdesivir under an EUA [33]. 
The NIH COVID-19 treatment guidelines also recommend 
the use of dexamethasone as an anti-inflammatory agent 
for hospitalized patients requiring supplemental oxygen and 
those with severe or critical illness [30]. Other therapies for 
SARS-CoV-2 infections, including convalescent plasma and 
monoclonal antibodies (specific proteins that are made to 
decrease the virus’s ability to make more copies), are being 
investigated through clinical trials in North Carolina and 
across the country. It should be noted that there is no rec-
ommended pre- or post-exposure therapy for SARS-CoV-2. 
Contact Tracing
Contact tracing is an important public health strategy 
for COVID-19 in order to identify people who have recently 
been in close contact with someone who is infected, allow 
rapid notification for testing, and provide support for nec-
essary resources if the contact becomes symptomatic [16]. 
The CDC has supported and led a nationwide, coordinated 
training effort to build a public health COVID-19 contact-
tracing workforce, and has responded to requests for assis-
tance from hotspot counties in the United States. In June 
2020, the CDC and the US Public Health Service (USPHS) 
deployed multidisciplinary teams to North Carolina to assist 
with case investigation, contact tracing, and data manage-
ment; the CDC Foundation also provided additional contact 
tracers to support local health departments in the state to 
manage these hotspots [34]. 
In addition to traditional contact tracing procedures, 
digital contact tracing tools like SlowCOVIDNC are now 
being utilized by public health to enhance efforts during 
this pandemic. SlowCOVIDNC uses Bluetooth technology 
to let users anonymously share a positive COVID-19 test 
result through an app, which can notify other users who may 
be close contacts [2]. NCDHHS is also using a COVID-19 
Community Team Outreach (CCTO) Tool, which provides a 
platform to manage cases and contacts, perform digital out-
reach, and store data in a central repository. CCTO provides 
local health departments access to contact-tracing data 
collected by other organizations during outbreak or cluster 
investigations [2]. 
Impact on our Communities
Since March 2020, numerous outbreaks or clusters of 
SARS-CoV-2 have been reported in North Carolina in congre-
gate living facilities, such as long-term residential care and 
table 2.
National Institutes of Health Criteria for SARS-CoV-2 Infections Based on Severity of Illnessa 
Severity of Illness Clinical Criteria  
Asymptomatic or presymptomatic  Individuals positive for SARS-CoV-2 using a virologic test (i.e., a nucleic acid amplification test or antigen test), but  
without symptoms consistent with COVID-19 
Mild  Individuals with any sign and symptom of COVID-19 (e.g., fever, cough, sore throat, malaise, headache, muscle  
pain, nausea, vomiting, diarrhea, loss of taste and smell) but without shortness of breath, dyspnea, or abnormal  
chest imaging
Moderate  Individuals with evidence of lower respiratory disease during clinical assessment or imaging and saturation of  
oxygen (SpO2) ≥94% on room air at sea level 
Severe  Individuals with SpO2 <94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of  
inspired oxygen (PaO2/FiO2) <300 mmHg, respiratory frequency >30 breaths per minute, or lung infiltrates >50% 
Critical  Individuals with respiratory failure, septic shock, and/or multiple organ dysfunction 
aNational Institutes of Health. COVID-19 Treatment Guidelines: What’s New in the Guidelines. NIH website. https://www.covid19treatmentguidelines.nih.gov/
whats-new. Updated October 9, 2020. Accessed October 16, 2020.
correctional facilities [2]. In this issue, Dr. Boucher notes the 
increased health complications and financial stressors for 
recipients of long-term care services and their caregivers, 
which contribute negatively to quality of care and often lead 
to social isolation [35]. He also provides recommendations 
for decreasing social isolation.
Child care programs have also been significantly affected 
by COVID-19 in the state, and Michelle Rivest reports 384 
COVID-19 child care clusters in North Carolina in this issue 
[36]. School-related closures have been widespread, and in 
this issue Dr. Boutzoukas and coauthors also note the impact 
of the COVID-19 pandemic on children, including decreased 
academic achievement and heightened food insecurity as a 
result of K-12 school closures [37]. Lastly, several universi-
ties in North Carolina also experienced clusters of COVID-19 
cases among undergraduate students despite extensive 
planning for reopening this fall [38], prompting a shift from 
in-person classes to online-only virtual learning at most 
institutions, which may affect the quality of higher educa-
tion among young people in our state. 
Public Health Strategies
In response to this pandemic, North Carolina’s strategy 
has involved a phased reopening of sectors/activities to 
minimize spread of SARS-CoV-2, and requirement of masks 
or face coverings in public locations (indoors and outdoors) 
when physical distancing of six feet is not possible. On 
May 8, 2020, North Carolina began “phase 1” of easing 
COVID-19 restrictions to help revive the economy while pro-
tecting public health. Based on the number of positive tests 
and hospitalizations for SARS-CoV-2 statewide, the state 
entered “phase 3” on October 2, 2020, which expanded out-
door venues for bars, movie theaters, and other entertain-
ment venues to 30% capacity. Public school districts and 
charter schools can choose to implement different opera-
tional plans for elementary schools (grades K-5), which 
involve use of masks and various approaches to physical dis-
tancing in classrooms and during other school activities [2]. 
Public health initiatives conducted at the local level will 
continue to be critical in the response to rapid increases in 
cases and clusters, and to improve access to testing and out-
reach among our communities. In this issue, Dr. Pease and 
coauthors describe the strategy used by one county health 
department in the state to curb the spread of COVID-19 in 
congregate living facilities, including the use of a strike team 
to rapidly assess and control outbreaks [39]. Dr. Fiscus and 
coauthors also report in this issue on how mobile testing 
units rapidly established by health systems across North 
Carolina can provide underserved residents critical access 
to diagnostics and care [40].
The COVID-19 pandemic continues to take a large toll in 
North Carolina and across the United States. As we face the 
uncertainties of a new year with COVID-19, our medical and 
public health community will need to remain steadfast in 
our messaging to the public, especially as vaccines become 
widely available for SARS-CoV-2. In this issue, Dr. Sturgill 
emphasizes the importance of consistent and accurate pub-
lic health messaging and patient education, based on scien-
tific and evidence-based resources [41]. 
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